TABLE 2.
Median symptom score for all treatment groups a different time points relative to enrolment, treatment and last follow-up
Baseline to last assessment before treatment |
Last assessment before treatment to first assessment after treatment |
First assessment after treatment to last assessment |
|||||||
---|---|---|---|---|---|---|---|---|---|
Baseline Median (Q1, Q3) |
Last Median (Q1, Q3) |
P† | Last Median (Q1, Q3) |
First Median (Q1, Q3) |
P† | First Median (Q1, Q3) |
Last Median (Q1, Q3) |
P | |
None* | 4 (2, 7) | 6 (2, 10) | <0.001 | - | - | - | - | - | - |
α-AR | 7 (4, 10) | 11 (6, 15) | <0.001 | 11 (7, 15) | 12 (6, 17) | 0.16 | 11 (6, 16) | 13 (8, 17) | < 0.001 |
5-ARI | 7 (3, 12) | 12 (7, 17) | <0.001 | 10 (6, 16) | 10 (6, 15) | 0.35 | 10 (6, 15) | 11 (6, 17) | 0.03 |
Vaporization | 11 (5, 17) | 18 (14, 22) | <0.001 | 15 (13, 20) | 9 (6, 11) | 0.001 | 10 (8, 12) | 15 (8, 20) | 0.84 |
TURP | 9 (4, 14) | 15 (10, 19) | <0.001 | 16 (11, 19) | 6 (2, 10) | <0.0001 | 7 (2, 12) | 8 (3, 13) | 0.07 |
α-ARs, α-adrenergic receptor inhibitors; 5-ARI, 5α-reductase inhibitors; TURP, transurethral resection of the prostate.
Median symptom score from baseline to last follow-up assessment.
t test P value.